NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

PN in NF1 cause substantial morbidity. In a phase I trial of selumetinib, 17/24 patients had a partial response (PR). This study evaluates the PR rate of PN to selumetinib and changes in PN-related morbidities. Patients 2-18 years with NF1, inoperable PN and ≥ 1 PN-related morbidity received continu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Gross, Andrea, Wolters, Pamela, Baldwin, Andrea, Dombi, Eva, Fisher, Michael J, Weiss, Brian, Kim, AeRang, Blakeley, Jaishri, Whitcomb, Patricia, Holmblad, Marielle, Maritin, Staci, Roderick, Marie Claire, Paul, Scott M, Therrien, Janet, Heisey, Kara, Doyle, Austin, Smith, Malcolm, Glod, John, Steinberg, Seth, Widemann, Brigitte C
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.515
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados